Jérôme TIOLLIER PhD, 58 years old joined INNATE PHARMA on September 2001. He currently holds the position of EVP Chief Development Officer overseeing product development programs in pharmaceutical, regulatory non-clinical operations and program management of the different mAbs of the company.

During previous years since 2001, he built the development team organization and manage multiple areas of drug development, including CMC toxicology, PK, drug non clinical demonstration, translational scientific research and clinical & regulatory operations up to early (Phase I & II) clinical phases of the different “first in class” mAbs of Innate portfolio. He participates to build the US operations as President of Innate Pharma Inc. and other corporate development activities. He graduated from C.Bernard University-Lyon as PhD and has a scientific background in cell biology and immunology.
Previously, he has been with IMEDEX SA (1986-1997) a French biotech spin off from Institut Mérieux at different position where he managed the development of different biological products from preclinical to early clinical stage (phase I/II) with the collaboration of internal R&D groups and CRO. Then he moves to Pasteur-Mérieux Transplant business unit (then acquired by SANGSTAT in 1998, now part of Sanofi Genzyme,) as Preclinical Director (1997-1999) and European R&D Director (1999-2001). In the positions, he managed different pharmaceutical product license building (Thymoglobuline, anti-LFA1 mAb, all IPH first in class mAbs) as well as global research projects.